Kintegral Advisory LLC Buys New Holdings in Moderna, Inc. $MRNA

Posted by Francis Steltz on Oct 18th, 2026

Kintegral Advisory LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 2,786 shares of the company’s stock, valued at approximately $536,000.

A number of other institutional investors have also made changes to their positions in MRNA. BlackRock Inc. bought a new stake in Moderna in the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new position in Moderna during the second quarter worth $564,272,000. Wellington Management Group LLP boosted its position in Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the period. First Trust Advisors LP boosted its position in Moderna by 59.3% during the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after purchasing an additional 891,072 shares during the period. Finally, Merck & Co. Inc. acquired a new position in shares of Moderna in the second quarter valued at $161,642,545. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a report on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective on the stock. Loop Capital set a $135.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Morgan Stanley lifted their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Finally, Evercore upped their price target on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $101.45.

Read Our Latest Stock Report on Moderna

Insider Activity at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $218.01 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $87.04 billion, a P/E ratio of -27.29 and a beta of 1.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $242.29. The firm has a 50-day moving average price of $156.66 and a two-hundred day moving average price of $90.88.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same period last year, the firm earned ($2.13) earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Upcoming melanoma and other cancer-vaccine data remain the main bullish catalyst. Earlier positive results from Moderna’s personalized cancer-vaccine collaboration with Merck have increased expectations that new data could support the pipeline and help sustain the stock’s gains. Merck and Moderna cancer vaccine strategy
Positive Sentiment: Investor interest has also been supported by strong momentum, healthcare-sector fund flows and optimism that Moderna’s pipeline could diversify the business beyond COVID-19 vaccines. Moderna rallies as money rotates into healthcare
Neutral Sentiment: President Stephen Hoge sold a combined 78,369 shares in transactions conducted under a pre-arranged Rule 10b5-1 plan. Although the sales may weigh on sentiment, they represented only a small portion of his remaining holdings and were not discretionary trades made during the current move. Moderna insider trading filing
Neutral Sentiment: A study comparing the stability of three mRNA vaccines in human blood may provide useful scientific context for the platform, but it does not appear to offer an immediate change to Moderna’s revenue outlook or valuation. mRNA vaccine stability study
Negative Sentiment: Profit-taking has intensified after Moderna became one of the market’s strongest performers, with analysts cautioning that the stock’s valuation now depends heavily on successful pipeline execution. Goldman Sachs raised its target to $137 but retained a Neutral rating, leaving the target substantially below recent trading levels. Moderna valuation debate
Negative Sentiment: The broader selloff in vaccine stocks, including declines in Novavax and BioNTech, has added sector-wide pressure. Investors are also wary of Moderna’s continuing losses and negative cash flow while awaiting the cancer-data catalyst. Vaccine-stock selloff

Moderna Profile

(Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.